​

Agios Pharmaceuticals Ownership | Who Owns Agios Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Agios Pharmaceuticals Ownership Summary


Agios Pharmaceuticals is owned by 113.15% institutional investors, 1.07% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 10.47% of AGIO shares. BB Biotech AG Ord is the top mutual fund, with 6.34% of its assets in Agios Pharmaceuticals shares.

AGIO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAgios Pharmaceuticals113.15%1.07%-14.22%
SectorHealthcare Stocks 129.40%12.08%-41.48%
IndustryBiotech Stocks 181.71%11.69%-93.40%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de6.23M10.47%$207.12M
Farallon capital management5.92M10.07%$219.59M
Vanguard group5.59M9.62%$152.28M
Blackrock4.86M8.55%$209.52M
Bellevue group3.71M6.41%$149.11M
Lynx1 capital management lp3.41M5.80%$126.51M
Morgan stanley3.44M5.78%$114.27M
State street3.26M5.49%$108.55M
D. e. shaw3.11M5.29%$115.30M
Vanguard portfolio management2.85M4.79%$94.77M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Lynx1 capital management lp3.41M24.92%$126.51M
Caligan partners lp1.13M5.95%$45.41M
Commodore capital lp2.34M4.58%$93.86M
Foresite capital management vi785.00K4.53%$29.13M
Cutter capital management, lp301.62K4.06%$9.91M
Bellevue group3.71M3.10%$149.11M
Paradigm biocapital advisors lp2.67M3.05%$107.32M
Parkman healthcare partners669.05K2.54%$24.83M
Adar1 capital management1.29M2.19%$47.80M
Exome asset management70.50K1.61%$2.62M

Top Buyers

HolderShares% AssetsChange
Morgan stanley3.44M0.01%2.47M
Assenagon asset management1.89M0.06%1.78M
Paradigm biocapital advisors lp2.67M3.05%1.53M
Adar1 capital management1.29M2.19%1.15M
Lynx1 capital management lp3.41M24.92%797.37K

Top Sellers

HolderShares% AssetsChange
Macquarie group---1.96M
T. rowe price investment management---1.49M
Bioimpact capital---1.31M
Frazier life sciences management---1.26M
Tcg crossover management---1.18M

New Positions

HolderShares% AssetsChangeValue
Renaissance505.60K0.02%505.60K$16.81M
Axa investment managers177.68K0.02%177.68K$7.13M
Norges bank145.09K0.00%145.09K$4.77M
Jain global91.65K0.01%91.65K$3.40M
Walleye capital56.60K0.00%56.60K$1.88M

Sold Out

HolderChange
Hughes financial services-1.00
National bank of canada /fi/-1.00
Dinuzzo private wealth-1.00
Riggs asset managment-3.00
Global financial private client-3.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20262551.19%67,312,9331.16%1130.88%1360.74%64-3.03%
Jun 30, 20262490.40%66,448,3535.41%1130.98%1349.84%64-16.88%
Mar 31, 2026246-3.91%63,038,2052.90%1080.98%123-13.99%767.04%
Dec 31, 2025165-31.82%34,473,117-45.71%590.49%89-24.58%49-28.99%
Sep 30, 20252299.05%60,859,3063.40%1051.02%1114.72%67-6.94%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
BB Biotech AG Ord3.71M6.34%124.59K
Vanguard MStar Total Stk Mkt Idx Invest1.90M3.19%8.33K
Vanguard Morn Total Stk Mkt Idx Investor1.89M3.18%718.00
Vanguard Total Stock Mkt Idx Inv1.89M3.18%718.00
Vanguard US Total Market Shares ETF1.79M3.12%2.35K
State Street® SPDR® S&P® Biotech ETF1.83M3.06%47.81K
Nomura US Small Cap Core Equity1.70M2.85%513.26K
Nomura Small Cap Core I1.70M2.83%-
iShares Russell 2000 ETF1.50M2.51%-
Macquarie Small Cap Core I1.43M2.46%-107.41K

Recent Insider Transactions


DateNameRoleActivityValue
Oct 26, 2026Gheuens Sarah Chief Medical OfficerSell$296.47K
Oct 21, 2026Gheuens Sarah Chief Medical OfficerSell$55.88K
Oct 22, 2026Gheuens Sarah Chief Medical OfficerSell$18.76K
Aug 04, 2026Gheuens Sarah Chief Medical OfficerSell$914.40K
Jul 01, 2026Gheuens Sarah Chief Medical OfficerSell$150.50K

Insider Transactions Trends


DateBuySell
2026 Q4-3
2026 Q3-2
2026 Q2-7
2026 Q1-22
2025 Q4-11

AGIO Ownership FAQ


Who Owns Agios Pharmaceuticals?

Agios Pharmaceuticals shareholders are primarily institutional investors at 113.15%, followed by 1.07% insiders and -14.22% retail investors. The average institutional ownership in Agios Pharmaceuticals's industry, Biotech Stocks , is 181.71%, which Agios Pharmaceuticals falls below.

Who owns the most shares of Agios Pharmaceuticals?

Agios Pharmaceuticals’s largest shareholders are Blackrock funding, inc. /de (6.23M shares, 10.47%), Farallon capital management (5.92M shares, 10.07%), and Vanguard group (5.59M shares, 9.62%). Together, they hold 30.16% of Agios Pharmaceuticals’s total shares outstanding.

Does Blackrock own Agios Pharmaceuticals?

Yes, BlackRock owns 8.55% of Agios Pharmaceuticals, totaling 4.86M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 209.52M$. In the last quarter, BlackRock increased its holdings by 200.91K shares, a 4.31% change.

Who is Agios Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Lynx1 capital management lp is Agios Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 24.92% of its assets in 3.41M Agios Pharmaceuticals shares, valued at 126.51M$.

Who is the top mutual fund holder of Agios Pharmaceuticals shares?

BB Biotech AG Ord is the top mutual fund holder of Agios Pharmaceuticals shares, with 6.34% of its total shares outstanding invested in 3.71M Agios Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools